1. Cornblath, M, Reisner, SH. Blood glucose in the neonate and its clinical significance. N Engl J Med 1965; 273: 378–381.
Google Scholar | Crossref | Medline | ISI2. Stanley, CA, Rozance, PJ, Thornton, PS, et al. Re-evaluating “transitional neonatal hypoglycemia”: mechanism and implications for management. J Pediatr 2015; 166: 1520–1525.e1521.
Google Scholar | Crossref | Medline3. Guemes, M, Hussain, K. Hyperinsulinemic hypoglycemia. Pediatr Clin North Am 2015; 62: 1017–1036.
Google Scholar | Crossref | Medline4. Steinkrauss, L, Lipman, TH, Hendell, CD, et al. Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism. J Pediatr Nurs 2005; 20: 109–118.
Google Scholar | Crossref | Medline5. Anchan, JC, Carr, NR, Ahmad, KA. Neonatal hypoglycemia: is there a neurodevelopmental impact in early childhood? J Perinatol 2019; 39: 4–7.
Google Scholar | Crossref | Medline6. Doyle, ME, Egan, JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 2003; 55: 105–131.
Google Scholar | Crossref | Medline7. Proglycem (diazoxide) . Silver Spring, MD: US Food and Drug Administration, 2015.
Google Scholar8. Welters, A, Lerch, C, Kummer, S, et al. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers. Orphanet J Rare Dis 2015; 10: 150.
Google Scholar | Crossref | Medline9. Theodorou, CM, Hirose, S. Necrotizing enterocolitis following diazoxide therapy for persistent neonatal hypoglycemia. J Pediatr Surg Case Rep 2020; 52: 101356.
Google Scholar | Crossref | Medline10. Prado, LA, Castro, M, Weisz, DE, et al. Necrotising enterocolitis in newborns receiving diazoxide. Arch Dis Child Fetal Neonatal Ed. Epub ahead of print 10 November 2020. DOI: 10.1136/archdischild-2020-319057
Google Scholar | Crossref11. Timlin, MR, Black, AB, Delaney, HM, et al. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol 2017; 38: 1247–1250.
Google Scholar | Crossref | Medline12. Kylat, RI. Pulmonary hypertension occurring with diazoxide use in a preterm infant with hypoglycemia. Drug Healthc Patient Saf 2019; 11: 7–10.
Google Scholar | Crossref | Medline13. US Food and Drug Administration . FDA drug safety communication: FDA warns about a serious lung condition in infants and newborns treated with Proglycem (diazoxide). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safetycommunication-fda-warns-about-serious-lung-condition-infants-and-newborns-treated (2015, accessed 25 January 2020).
Google Scholar14. Chen, SC, Dastamani, A, Pintus, D, et al. Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: recommendations from a multicentre study in the United Kingdom. Clin Endocrinol (Oxf) 2019; 91: 770–775.
Google Scholar | Crossref | Medline15. Herrera, A, Vajravelu, ME, Givler, S, et al. Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide. J Clin Endocrinol Metab 2018; 103: 4365–4372.
Google Scholar | Crossref | Medline16. Thornton, P, Truong, L, Reynolds, C, et al. Rate of serious adverse events associated with diazoxide treatment of patients with hyperinsulinism. Horm Res Paediatr 2019; 91: 25–32.
Google Scholar | Crossref | Medline17. Yoshida, K, Kawai, M, Marumo, C, et al. High prevalence of severe circulatory complications with diazoxide in premature infants. Neonatology 2014; 105: 166–171.
Google Scholar | Crossref | Medline18. Demirel, F, Unal, S, Cetin, II, et al. Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide. J Pediatr Endocrinol Metab 2011; 24: 603–605.
Google Scholar | Crossref | Medline19. Gray, KD, Dudash, K, Escobar, C, et al. Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol 2018; 38: 1496–1502.
Google Scholar | Crossref | Medline20. Thomas, P, Ye, Y, Lightner, E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet 1996; 5: 1809–1812.
Google Scholar | Crossref | Medline | ISI21. Thomas, PM, Cote, GJ, Wohllk, N, et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995; 268: 426–429.
Google Scholar | Crossref | Medline | ISI22. Fafoula, O, Alkhayyat, H, Hussain, K. Prolonged hyperinsulinaemic hypoglycaemia in newborns with intrauterine growth retardation. Arch Dis Child Fetal Neonatal Ed 2006; 91: F467.
Google Scholar | Crossref | Medline23. Shiu, YK, Lo, FM, TS, Lam, et al. A case of partial trisomy 13 presenting with hyperinsulinaemic hypoglycaemia. Hong Kong Med J 2003; 9: 381–383.
Google Scholar | Medline24. Bastug, O, Ozturk, MA, Dogan, MS, et al. The presence of adrenomegaly and transient hyperinsulinemic hypoglycemia in a newborn with trisomy 13: association or coincidence? J Clin Neonatol 2015; 4: 57–59.
Google Scholar | Crossref25. Thornton, PS, Stanley, CA, De Leon, DD, et al. Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J Pediatr 2015; 167: 238–245.
Google Scholar | Crossref | Medline26. Okada, S, Fukunaga, S, Ohta, H, et al. Cerebral insufficiency caused by diazoxide in a premature neonate with congenital hyperinsulinism. Neuropediatrics 2020; 51: 211–214.
Google Scholar | Crossref | Medline